At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184
In Brief
A Phase 2 clinical trial evaluating cabozantinib, laboratory biomarker analysis, and 1 other intervention for Bone Metastases and 3 related conditions. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This study is being done to help researchers understand more about prostate cancer that has spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to better understand the effect of an experimental drug called XL184 (or cabozantinib) on bone disease. The other purposes of the study are to better understand the effect of XL184 on prostate cancer progression, bone pain, and on any cancer cells that patients may have circulating within the blood (called circulating tumor cells)
Study Details
Timeline
Interventions
Given PO
Correlative studies
Undergo MRI